Neurocrine Biosciences Inc.

07/31/2026 | Press release | Distributed by Public on 07/31/2026 14:11

Initial Registration Statement for Employee Benefit Plan (Form S-8)


As filed with the Securities and Exchange Commission on July 31, 2026

Registration No. 333-


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
NEUROCRINE BIOSCIENCES, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware 33-0525145
(State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.)
6027 Edgewood Bend Court
San Diego, CA 92130
(Address of Principal Executive Offices)
Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan
(Full Title of the Plan)
Kyle W. Gano, Ph.D.
Chief Executive Officer
Neurocrine Biosciences, Inc.
6027 Edgewood Bend Court
San Diego, CA 92130
(Name and Address of Agent for Service)
(858) 617-7600
(Telephone Number, Including Area Code, of Agent for Service)





Copies to:
Darin M. Lippoldt Jason L. Kent, Esq.
Chief Legal Officer Carlos A. Ramirez, Esq.
Neurocrine Biosciences, Inc. Cooley LLP
6027 Edgewood Bend Court 10265 Science Center Drive
San Diego, CA 92130 San Diego, CA 92121
(858) 617-7600 (858) 550-6000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☒ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐





INCORPORATION BY REFERENCE OF CONTENTS
OF REGISTRATION STATEMENT ON FORM S-8
This Registration Statement on Form S-8 is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement on Form S-8 relating to the same benefit plan is effective. This Registration Statement on Form S-8 registers the offer and sale of an additional 4,000,000 shares of the Registrant's common stock for issuance under the Neurocrine Biosciences, Inc. 2025 Equity Incentive Plan (as amended, the "2025 Plan"). The Registrant previously registered shares of its common stock for issuance under the 2025 Plan on May 21, 2025 (File No. 333-287477). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statement referenced above.

ITEM 8. EXHIBITS.
Exhibit
4.1 Description:
Reference: Incorporated by reference to Exhibit 3.1 of the Registrant's Quarterly Report on Form 10-Q filed on November 5, 2018
4.2 Description:
Reference: Incorporated by reference to Exhibit 3.2 of the Registrant's Quarterly Report on Form 10-Q filed on October 30, 2024
4.3 Description:
Reference: Incorporated by reference to the Registrant's Registration Statement on Form S-1 (Registration No. 333-03172)
4.4 Description:
Reference: Incorporated by reference to Exhibit 4.2 of the Registrant's Annual Report on Form 10-K filed on February 1, 2026
5.1 Description:
Opinion of Cooley LLP
23.1 Description:
Consent of Independent Registered Public Accounting Firm
23.2 Description:
Consent of Cooley LLP (included in Exhibit 5.1)
24.1 Description:
Power of Attorney (included on the signature page hereto)
99.1 Description:
Reference: Incorporated by reference to Exhibit 10.3 of the Registrant's Quarterly Report on Form 10-Q filed on July 31, 2026
107 Description:
Filing Fee Table


SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on July 31, 2026.
NEUROCRINE BIOSCIENCES, INC.
By: /s/ Kyle W. Gano
Kyle W. Gano, Ph.D.
Chief Executive Officer


POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints KYLE W. GANO, PH.D., MATTHEW C. ABERNETHY and DARIN M. LIPPOLDT, and each or either of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature Title Date
/s/ Kyle W. Gano Chief Executive Officer and Director July 31, 2026
Kyle W. Gano, Ph.D. (Principal Executive Officer)
/s/ Matthew C. Abernethy Chief Financial Officer July 31, 2026
Matthew C. Abernethy (Principal Financial and Accounting Officer)
/s/ William H. Rastetter Chairman of the Board of Directors July 31, 2026
William H. Rastetter, Ph.D.
/s/ Kevin C. Gorman Director July 31, 2026
Kevin C. Gorman, Ph.D.
/s/ Gary A. Lyons Director July 31, 2026
Gary A. Lyons
/s/ Johanna Mercier Director July 31, 2026
Johanna Mercier
/s/ George J. Morrow Director July 31, 2026
George J. Morrow
/s/ Leslie V. Norwalk Director July 31, 2026
Leslie V. Norwalk
/s/ Christine A. Poon Director July 31, 2026
Christine A. Poon
/s/ Richard F. Pops Director July 31, 2026
Richard F. Pops
/s/ Shalini Sharp Director July 31, 2026
Shalini Sharp
/s/ Stephen A. Sherwin
Director July 31, 2026
Stephen A. Sherwin, M.D.

Neurocrine Biosciences Inc. published this content on July 31, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on July 31, 2026 at 20:11 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]